AzTrials
AzTrials

Septic ShockNCT02835157

Balanced Crystalloid vs. Saline in Children With Septic Shock

A study testing Balanced crystalloid solution and 0.9%sodium chloride in people with Septic Shock and Shock, run by All India Institute of Medical Sciences at 4 sites in India.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all… Read more about this study

Who is it for?
Ages 2 months to 15 years
Conditions the study is for
Septic Shock, Shock
What is being tested?
Balanced crystalloid solution and 0.9%sodium chloride
Could I receive a placebo?
No, everyone receives an active treatment
How many people
708 participants
Where
4 sitesIndia
Study dates
1 Apr 2017to 15 Jan 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 months to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Children 2 month to ≤ 15 years with features of septic shock - defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension

Who cannot join

  • Children receiving fluid boluses before enrollment
  • Children with cardiogenic shock
  • Known patient with chronic kidney disease with baseline deranged renal function (eGFR < 90 ml/1.73 m2/min)
  • Severe malnutrition
  • Children whose parents refuse to give an informed consent

Trial locations and contacts

4 sites in 1 country.

India4 sites
  • St Johns Medical College and Hospital

    Bengaluru, Karnataka, 560034

  • PGIMER

    Chandigarh

  • All India Institute of Medical Sciences

    New Delhi, National Capital Territory of Delhi, 110029

  • JIPMER

    Puducherry, 605006

Other trials in India

About this study

Official title: Multiple Electrolyte Solution vs. Saline in Pediatric Septic Shock

Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all other fluids available and commonly used. However, normal saline has its own set of undesired physicochemical actions. Emerging data strongly indicate the increased incidence of hyperchloremia, metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, clearly decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. The results favored balanced solutions in comparison to normal saline. Recent systematic reviews comparing balanced or buffered versus non-buffered fluids for surgery in adults favored the former solution as the metabolic derangements were less with the use of this type of fluid. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.

Given this background, the investigators decided to compare the effect of two solutions on the incidence of acute kidney injury in children resuscitated with either of the two fluids. Children receiving at least one fluid bolus at 20 ml/kg in the first hour would be enrolled and followed up for the proposed outcome variables. The investigators plan to enroll 708 patients over a period of 3 years. The investigators believe that the proposed study will provide answer to the research question of which of the fluids could be preferred for resuscitation.

Read the detailed description

Background

Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Emerging data strongly indicate the increased incidence of hyperchloremic metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline in critically ill adults in shock. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, have shown to decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline.

Objectives

Primary To examine if use of 'balanced crystalloids (multiple electrolyte solution)" results in lower incidence of new or progressive Acute kidney injury (defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours) in the first seven days after initial fluid resuscitation as compared to saline.

Secondary

To evaluate the difference if any, between two fluid types with regard to the following secondary objectives such as:

  1. Incidence of hyperchloremia (defined as serum chloride levels >108 mEq/L) at 6, 24, 48 and 72 hrs of fluid resuscitation.
  2. Incidence of metabolic acidosis at 6, 24, 48 and 72 hrs of fluid resuscitation.
  3. Requirement of fluid boluses in first 6 hrs and total fluids in first 24 hours, 48 hours and 72 hours.
  4. Proportion of patients achieving the pre-determined therapeutic end points at 6, 24, 48 hours and 72 hours after fluid resuscitation.
  5. Need for inotrope therapy in first 7 days.
  6. Change in SOFA scores and PELOD scores at 24 hours and 48 hours.
  7. Time to resolution of AKI.
  8. In- ICU mortality rates.
  9. Ventilator free days, ICU free days and Hospital free days.

Site of study

Pediatric emergency and PICU, Department of Pediatrics, All India Institute of medical Sciences,New Delhi

Other sites

PGIMER, Chandigarh, JIPMER Puducherry and St Johns Medical College Bengaluru

Study Design

Randomized controlled trial (safety and superiority for kidney injury). Multicenter trial.

Study Duration

3 years

Study definitions

Septic shock is defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension such as decreased mental status, prolonged capillary refill of >2 secs (cold shock) or flash capillary refill (warm shock), diminished (cold shock) or bounding (warm shock) peripheral pulses, mottled cool extremities (cold shock), or decreased urine output of <1 ml/kg/hr).

Therapeutic end points

  • Normal heart rate
  • Appropriate-for-age mean arterial pressure (MAP) measured non-invasively;
  • Normal pulses with no difference between peripheral and central pulses, warm extremities;
  • Capillary refill time <2 seconds;
  • Normal mental status;
  • Urine output ≥ 1mL/kg/hr,

Hyperchloremia: Defined as serum chloride value of >108 meq/L, based on our laboratory cut off of 98-108 meq/L Metabolic acidosis: pH of less than 7.35 with serum bicarbonate < 24 meq/L with low to normal pCO2 (<40 mm Hg)

Acute kidney injury: An abrupt (within 48-hr) reduction in kidney function defined as an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl, an increase in serum creatinine of more than or equal to 1.5 fold from the value preceding the abnormal value, or reduction in urine output (oliguria of less than 0.5 ml/kg per hour for >6-hr).

Enrollment

All children with features of shock as per standard definitions will be screened for eligibility. Of these, children who require at least one fluid bolus of 20 ml/kg will be enrolled. The eligible participants would be enrolled after obtaining informed consent from one of the parents.

Randomization

Once enrolled, the participants would be randomized into 2 groups. 'MES' or 'study group' will receive the balanced fluids and 'saline' or 'control group' will receive 0.9% saline. Process of randomization will be done by an investigator who will have no further role in collecting the baseline variables, applying intervention or analysis of outcome(s). Block randomization will be done in varying block sizes of 2 to 8. The random number table generated from computer software would be used for this purpose.

Sample size estimation

The investigators calculated that a sample size of 354 patients in each group (708 total) would be required to detect an absolute reduction in incidence of AKI from 25% (current incidence in children with shock in the unit) to 15% assuming a two-sided α level of 0.05 and a statistical power of 90%. The sample size was calculated using Stata 11. The investigators expect the required sample size to be collected within 3 years period in the three centers.

Conditions
Septic Shock, Shock
Being tested
Balanced crystalloid solution, 0.9%sodium chloride
Keywords
Normal saline, Multiple electrolyte solution, Septic shock, Children, Hyperchloremia, Acute kidney injury, 0.9% saline, Balanced crystalloid
Medical subject headings
Shock, Septic, Shock, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Balanced crystalloid solutionDrug

    Also called Plasma-Lyte A 148, Multiple electrolyte solution

    Multiple electrolyte solution as boluses would be administered.

  • 0.9%sodium chlorideDrug

    Also called Saline

    saline as boluses would be administered

Study groups in NCT02835157
Study groupRoleWhat they receive
Balanced crystalloid or multiple electrolyte solution groupExperimentalAfter enrollment, a fluid bolus comprising of 'multiple electrolyte solution (Plasma-Lyte P)' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
Receives: Drug: Balanced crystalloid solution
0.9% saline or saline groupActive comparatorAfter enrollment, a fluid bolus comprising of 'saline' solution at a dose of 20 ml/kg over 15-20 minutes (recommended) with careful monitoring for features of fluid overload would be administered to each child. Fluid resuscitation will be targeted at achieving the therapeutic end points as given in study definitions. After this the management protocol will be as per recommendations of the American College of Critical Care Medicine 2017 for septic shock in children.
Receives: Drug: 0.9%sodium chloride

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours

    Incidence of new or progressive AKI in first 7 days after randomization/ intervention

    Measured: From the time of randomization/intervention to 7 days of admission

Secondary outcomes (8)
  1. Proportion of patients with serum chloride levels > 108 meq/L at admission, 6, 24, 48 and 72 hours

    Incidence of hyperchloremia

    Measured: At 6, 24, 48 and 72 hours after randomization

  2. Number of fluid boluses received in the first 6 hours after randomization

    Total number of fluid boluses received in the first 6 hours after randomization/intervention

    Measured: From the time of randomization to 6 hours

  3. Total fluids received in the first 24 hours, 24-48 hours and 48-72hrs in ml/kg after randomization

    Total fluids received in first 24 hours, 24-48 hours and 48-72 hours

    Measured: From the time of randomization to 72 hours

  4. Mortality (serious adverse event)

    Death during ICU course

    Measured: From the time of randomization till death or discharge from ICU, whichever came first assessed upto 100 days

  5. Time to resolution of AKI

    Time taken for resolution of AKI

    Measured: From the time of onset of AKI after randomization till death or discharge from hospital, whichever came first assessed upto 100 days

  6. SOFA scores at 24 and 48 hours after randomization

    Comparison of SOFA scores in both groups at 24 hours and 48 hours after randomization

    Measured: At 24 and 48 hours after randomization

  7. PELOD scores at 24 and 48 hours after randomization

    Comparison of PELOD scores in both groups at 24 hours and 48 hours after randomization

    Measured: At 24 and 48 hours after randomization

  8. Incidence of metabolic acidosis at 6, 24, 48 and 72 hours after randomization

    Comparison of number of children in both groups with acidosis at 6, 24, 48 and 72 hours after randomization

    Measured: At admission and at 6, 24, 48 and 72 hours after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jul 2016 (estimated)
  2. Study start1 Apr 2017
  3. Primary completion15 Jan 2020
  4. Study completion15 Jan 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The enrolled children will be randomized to either balanced crystalloid (Plasma-Lyte A or multiple electrolyte solutions or MES group) or 0.9% saline (saline group).
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
708 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02835157
Sponsor's protocol ID
IEC/NP-424/09.10.2015
Status last verified
Dec 2021
First submitted
1 Mar 2016
Last updated
21 Dec 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual patient data will not be shared

Publications

  • Sankar J, Muralidharan J, Lalitha AV, Rameshkumar R, Pathak M, Das RR, Nadkarni VM, Ismail J, Subramanian M, Nallasamy K, Dev N, Kumar UV, Kumar K, Sharma T, Jaravta K, Thakur N, Aggarwal P, Jat KR, Kabra SK, Lodha R. Multiple Electrolytes Solution Versus Saline as Bolus Fluid for Resuscitation in Pediatric Septic Shock: A Multicenter Randomized Clinical Trial. Crit Care Med. 2023 Nov 1;51(11):1449-1460. doi: 10.1097/CCM.0000000000005952. Epub 2023 Jun 9.

    PubMed 37294145

Questions about this trial

What is this clinical trial studying?

A study testing Balanced crystalloid solution and 0.9%sodium chloride in people with Septic Shock and Shock, run by All India Institute of Medical Sciences at 4 sites in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours (time frame: From the time of randomization/intervention to 7 days of admission). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02835157, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in